insights_auto
Why is ALKS down 2.69%?
Dive Deeperchevron_right
ALKS:NASDAQ
Alkermes Plc
$44.94
arrow_downward
-2.69%(-1.24) 1D
$45.50
arrow_upward
+1.25% (+0.56)bedtimeAfter hours
Closed: Nov 20, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALKS...
Open
$45.79
High
$46.89
Low
$44.83
Mkt. cap
7.55B
Avg. vol.
1.71M
Volume
1.08M
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
Open
$45.79
High
$46.89
Low
$44.83
Mkt. cap
7.55B
Avg. vol.
1.71M
Volume
1.08M
52-wk high
$55.67
52-wk low
$27.00
EPS
-$0.01
Beta
0.29
Shares outstanding
168.04M
No. of employees
2K
News stories
From web sources and news partners
Stocks Down Under
·
5 hours ago
Alkermes (NDQ:ALKS): The Neuroscience Company Hiding Inside A Sleep Stock
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealkermes.com